Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia

ISSN: 1875-6182 (Online)
ISSN: 1871-5257 (Print)

Volume 15, 3 Issues, 2017

Download PDF Flyer

Cardiovascular & Hematological Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Cardiovascular & Hematological Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Debabrata Mukherjee
Department of Internal Medicine Texas Tech University
El Paso, TX

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia

Cardiovascular & Hematological Agents in Medicinal Chemistry, 11(4): 281-288.

Author(s): Maryna Popp Switzer, Azikiwe C. Nwosu, Zinnia San Juan and Debabrata Mukherjee.

Affiliation: Department of Internal Medicine, Professor of Internal Medicine, Texas Tech University, 4800 Alberta Avenue, El Paso, Texas 79905, USA.


PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) protein plays an important role in LDL cholesterol (LDL-C) metabolism, due to its role in the degradation of the LDL receptor. Preliminary clinical data of PCSK9 inhibition are quite promising and indicate that PCSK9 inhibition may be a novel strategy for the treatment of dyslipidemia particularly for those with refractory hypercholesterolemia, statin intolerance, or an elevated lipoprotein (a) level and associated cardiovascular diseases. Furthermore, development of PCSK9 inhibitor is an excellent example of “bench to bedside” concept where discovery of a genetic mutation was translated into a novel therapy to address unmet clinical needs. Although several approaches have been attempted to inhibit PCSK9 activity including small molecules, gene silencing and inhibitory antibodies, the most promising approach appears to be the use of monoclonal antibodies with a 50 -70% LDL cholesterol reduction on top of maximal doses of statins. In this article, we review the pharmacology of PCSK9 and summarize findings from key clinical studies using PCSK9 inhibitors.


Antibodies, atherosclerosis, cardiovascular disease, cholesterol, dyslipidemia, inhibitors, lipoprotein metabolism, lipoprotein receptors, low density, proprotein convertase subtilisin/kexin type 9.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 4
First Page: 281
Last Page: 288
Page Count: 8
DOI: 10.2174/1871525712999140303123027
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science